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In Situ Identification of Genes Regulated Specifically
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Carl-Henrik Heldin4, Johan Botling5, Fredrik Ponten5 and Arne O¨stman1
Basal cell carcinoma (BCC) is characterized by slow growth, virtual absence of metastases, and strong stroma-
dependency. Cancer-associated fibroblasts (CAFs) in the tumor stroma influence tumor growth, invasion, and
metastasis. To comprehensively characterize CAFs of BCC in their in situ cancer environment, laser capture
microdissection, linear gene amplification, microarray analysis, and quantitative real-time PCR (qRT-PCR) were
combined. Pair-wise comparison of gene expression of microdissected CAFs and corresponding normal
perifollicular fibroblasts identified 65 genes that were significantly upregulated in at least two of three different
patients. Among the annotated genes, as many as 13 genes encoded secreted proteins, of which six were
previously implicated as CAF-associated proteins in various tumor types. Four of the seven novel CAF genes –
matrix Gla-protein, secreted frizzled-related protein 2, angiopoietin-related protein-2, and platelet-derived
growth factor receptor-like protein – were selected for further analyses by qRT-PCR and were found to be
frequently upregulated in CAFs of three independent BCC tissues. Analyses of CAFs from squamous cell cancer,
prostate cancer, and colon cancer did not indicate that these genes were upregulated in these cancers. This
study thus validates a novel approach for comprehensive characterization CAFs in their in situ environment of
BCC. The results suggest a specific expression profile of CAFs in BCC possibly accounting for disease-specific
pathological roles.
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INTRODUCTION
Basal cell carcinoma (BCC) accounts for approximately 80%
of all non-melanoma skin cancers (Rubin et al., 2005). UV
radiation is the most important risk factor, and BCC arises
typically in sun-exposed body areas and incidence rates are
highest among elderly men. BCC is characterized by slow
tumor growth and develops only in skin containing hair
follicles. A stem cell located in the hair follicle or in the basal
interfollicular epidermis has been suggested as the progenitor
for a clonal expansion of BCC cells embedded in a polyclonal
connective tissue stroma (Asplund et al., 2005). Although
BCC exerts locally invasive properties and can grow highly
destructive, the development of metastases is extremely rare
(Rubin et al., 2005).
Dysregulation of the sonic hedgehog-patched signaling
pathway is believed to represent a central event for
tumorigenesis and most tumors display mutations in the
patched gene (PTCH, Zedan et al., 2001; Lacour, 2002). Loss-
of-function mutations of PTCH1 have been detected in
30–40% of sporadic cases of BCC (Gailani et al., 1996; Kim
et al., 2002). The absence of PTCH1 leads to a constitutive
activation of smoothened homolog (SMO) and consequently
to a permanent activation of target genes (Tilli et al., 2005).
Furthermore, gain of function mutations were identified in
sonic hedgehog, SMO, and the glioma-associated oncogene
GLI, also stressing the importance of the sonic hedgehog
pathway in BCC. In addition, UV-induced mutations in the
p53 gene are described in approximately 50% of all cases of
sporadic BCC (Ziegler et al., 1993; Ling et al., 2001).
The specific growth pattern and the inability of BCC to
grow in other organs indicate an unconditional requirement
for interactions with a specific stroma derived from the
dermis (Fusenig, 1994). The mechanisms whereby the
microenvironment influences the process of tumorigenesis
and possibly promotes or inhibits cancer proliferation and
invasion of BCC are largely unknown.
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The interactions between neoplastic epithelial cells and
surrounding mesenchymal cells are attracting increasing
attention (De Wever and Mareel, 2003; Bhowmick et al.,
2004; Micke and O¨stman, 2004; Mueller and Fusenig, 2004).
Recent studies have identified proteases, secreted growth
regulators, and extracellular matrix proteins frequently
upregulated in the stroma of different cancer types (Fukumura
et al., 1998; Vitolo et al., 2001; Tuxhorn et al., 2002; van
Kempen et al., 2004). Fibroblasts in the vicinity to cancer
cells are considered to be the most important source for these
proteins. Because of their morphology and contractile
properties they are often termed myofibroblasts, cancer-
associated fibroblasts (CAFs) or tumor-associated fibroblasts
(De Wever and Mareel, 2003; Micke and O¨stman, 2005).
A number of mechanisms have been suggested, whereby
CAFs contribute to tumor growth. These include secretion of
growth factors acting on tumor cells, as well as production of
angiogenic factors like vascular endothelial growth factor and
platelet-derived growth factor (PDGF) (Fukumura et al., 1998;
LeBedis et al., 2002; De Wever et al., 2004). Most recently,
the chemokine stromal-derived factor (SDF1, CXCL12) was
identified as a potent tumor-promoting factor secreted by
CAFs, acting by supporting angiogenesis through the recruit-
ment of endothelial progenitor cells (Orimo et al., 2005). In
the opposite direction, the active recruitment of fibroblasts by
cancer cells was convincingly demonstrated in animal
models that used genetically modified cell lines (Elliott
et al., 1992; Hast et al., 2002; Furuhashi et al., 2004).
Studies evaluating the role of CAFs in BCC are scant.
Additionally, many analyses of CAFs in other cancer
types relied mostly on in vitro studies, and are thus hampered
by the susceptibility of alterations in gene expression
caused by culture conditions. Also, many animal studies of
human cancers have to rely on immune-compromised
mice unable to properly reflect the natural in vivo cancer
microenvironment.
In order to comprehensively characterize CAFs in human
BCC and to avoid artificial, confounding variables, the
combination of laser capture microdissection, microarray-,
and quantitative real-time PCR (qRT-PCR) analyses was used
to determine the gene expression profile of human CAFs in
situ. These profiles were compared with fibroblasts derived
from histologically normal skin from the same patients. The
specificity of the gene alterations of CAFs in BCC was further
evaluated by comparisons with the gene expression profile of
CAFs derived from other cancers.
RESULTS
Gene expression profiling of microdissected perifollicular
fibroblasts and CAFs from three cases of BCC
Approximately 1,000 cells of intra-lesion CAFs of BCC and
normal perifollicular fibroblasts were isolated from each
patient (n¼3) by laser capture microdissection. The amount
of complementary DNA (cDNA) template for the later
amplifications was estimated using qRT-PCR and ranged
between 0.5 and 5 ng in the individual preparations. After
linear RNA amplification, the expression profiles of the three
independently isolated pairs of normal fibroblasts and CAFs
were analyzed by competitive microarrray analysis on cDNA
chips containing approximately 10,000 features correspond-
ing to 6,000 genes.
Genes showing at least 1.7-fold upregulation of the
average and significant differences from 1 (t-test, Po0.05)
were defined as upregulated in each of the three comparisons
of expression levels in CAFs with their physiological counter-
part. Using these criteria, 681, 228, and 49 features were
found to be upregulated in the three individual CAF
populations (Figure 1). On the other hand, 552, 84, and 75
cDNA elements were downregulated using corresponding
criteria (t-test, Po0.05, mean expression o0.57).
Validation of array results by qRT-PCR
To confirm that these results reflected true differences, and
were not introduced through erratic amplification, the
expression of selected genes was analyzed in the remaining
unamplified RNA. A total of 14 paired qRT-PCR reactions
were performed in this context (Table 1). Nine of the analyses
investigated the expression of genes identified as differen-
tially expressed in the array experiment. In all these cases, the
differential expression was confirmed by qRT-PCR analyses of
cDNA of unamplified mRNA. The expression differences as
determined by qRT-PCR were, in general, higher than
indicated by the array analyses.
It can therefore be concluded from this part of the analyses
that the amplification and array procedures yield few, if any,
false-positive results and that the genes identified in the array
experiment after RNA amplification indeed display differen-
tial expression in CAFs and normal fibroblasts.
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Figure 1. Identification of genes upregulated in CAFs of BCC from three
patients. The analysis of three different samples yielded three lists of
upregulated features of which 78 were upregulated inX2 of the samples. The
78 features corresponded to 65 unique genes, of which 42 were annotated
genes. Thirteen of these genes encoded secreted proteins (growth factors,
extracellular matrix proteins, proteases). Six of these genes had been
implicated as tumor stroma proteins of other tumor types than BCC. The other
seven represent novel ‘‘CAF-specific’’ proteins. SPARC, secreted protein,
acidic, cysteine-rich; DCN, decorin; LAMA2, laminin-alpha2/merosin;
MMP11, matrix metalloproteinase 11; COL5A2, collagen type Va2; TFPI,
tissue factor pathway inhibitor; PDGFRL, platelet-derived growth factor
receptor-like protein; SFRP2, secreted frizzled-related protein 2; ANGPTL2,
angiopoietin-related protein-2; CTSK, cathepsin K; MGP, matrix Gla-protein;
CILP, cartilage intermediate layer protein; DPT, dermatopontin.
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Identification of 42 genes commonly upregulated in
BCC-derived CAFs
The three expression lists were combined to identify genes
being commonly up- or downregulated in BCC-derived CAFs.
As shown in Figure 1, a striking overlap between the three
gene lists was observed. Seven elements were found to be
upregulated in all three CAF preparations, whereas a total of
78 elements were upregulated in at least two of the CAF
populations (Figure 1). The 78 upregulated features corre-
sponded to 65 different genes. Of the 65 genes, 42 were well-
annotated genes, whereas 23 were annotated as expressed
sequence tags or putative genes. Among the 42 annotated
genes, as many as 13 were genes encoding secreted growth
regulators, proteases, or extracellular matrix components
(Table S1a). Additional genes encoded proteins involved in
signal transduction, cytoskeleton organization, and metabolic
processes.
Combining the downregulated feature lists, 22 elements
were identified that were downregulated in at least two of
three CAF preparations, corresponding to 16 annotated genes
(Table S1b). The proteins encoded by these cDNA elements
were associated with immunity, apoptosis, cytoskeleton,
antiviral activity, and mitosis. For further analyses, we
focused on the commonly upregulated genes.
CAFs have been implicated both in cross-talk with other
tumor cell types and in matrix-remodeling. The set of 13
upregulated genes with properties indicating active roles in
these processes were therefore analyzed in some more detail.
Among these 13 genes were six proteins that have previously
been shown to be upregulated in tumor stroma of various
tumor types: secreted protein, acidic, cysteine-rich (SPARC),
decorin (DCN), laminin-alpha2/merosin, matrix metallopro-
teinase 11 (MMP11), collagen type Va2, and tissue factor
pathway inhibitor (Kosmehl et al., 1999; Le Bail et al., 1999;
Boulay et al., 2001; Fischer et al., 2001; Vitolo et al., 2001;
Andarawewa et al., 2003; Koukourakis et al., 2003; Selvey
et al., 2004). Moreover, two of these genes, DCN and
MMP11, had previously been shown to be frequently
upregulated in the tumor stroma of human BCC, underlining
the validity of our approach (Hunzelmann et al., 1995;
Thewes et al., 1999). The remaining seven genes (platelet-
derived growth factor receptor-like protein (PDGFRL),
secreted frizzled-related protein 2 (SFRP2), angiopoietin-
related protein 2 (ANGPTL2), cathepsin K (CTSK), matrix Gla-
protein (MGP), cartilage intermediate layer protein (CILP),
dermatopontin (DPT)) were identified as novel CAF-asso-
ciated genes previously not recognized in the context of
tumor–stroma interaction.
To further validate the upregulation of these novel CAF-
associated genes in BCC, the expression of four of the seven
novel CAF genes was analyzed in normal fibroblasts and
CAFs from three additional BCC patients by qRT-PCR. As
shown in Figure 2, upregulation in at least two of the three
cases was observed for all selected genes.
We thus conclude that a novel set of genes showing
consistent upregulation in BCC-derived CAFs has been
identified and note that a large fraction of these genes has
functional characteristics suggesting active involvement in
the cross-talk between BCC and CAFs, as well as in matrix re-
modeling.
Table 1. qRT-PCR evaluation of microarray results
Microarray qRT-PCR
Upregulated
PLIN1 (pat. 1) 17.3 471.8
SDF12 (pat. 1) 6.9 3105.7
PTN1 (pat. 3) 3.4 4.0
DCN1 (pat. 2) 1.7 8.2
UBN1 (pat. 2) 3.7 2.0
COL5A2 (pat. 2) 2.5 68.6
COL5A2 (pat. 3) 2.8 8.3
Downregulated
PLIN1 (pat. 3) 0.4 0.2
SOX3 (pat. 1) 0.3 0.5
Not regulated
UBN1 (pat. 3) 0.8 0.8
PTN1 (pat. 2) 0.8 1.6
DCN1 (pat. 3) 1.5 2.2
SDF12 (pat. 2) 1.2 187.5
SDF12 (pat. 3) 0.6 0.4
CAF, cancer-associated fibroblast; cDNA, complementary DNA;
COL5A2, collagen type Va2; DCN, decorin; PLIN, perilipin; PTN,
pleiotrophin (heparin binding growth factor 8, neurite growth-promoting
factor 1); qRT-PCR, quantitative real-time PCR; SDF1, stromal-derived
factor 1; SOX9, transcription factor SOX9; UBN1, ubinuclein 1.
Expression of selected genes in CAFs and normal fibroblasts was evaluated
in the non-amplified material of patients 1–3 with qRT-PCR. The ratios of
the gene expression in CAFs and in normal fibroblasts were determined.
Results are displayed according to the regulation in the array analysis of
amplified material (gene expression in CAFs/normal fibroblasts) and
compared with the results of the qRT-PCR of non-amplified material.
1Mean of two cDNA elements on the 10K array.
2Mean of four cDNA elements on the 10K array.
3Mean of three cDNA elements on the 10K array.
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Figure 2. qRT-PCR analyses of non-amplified RNA from additional
independent CAF preparations. Expression of four selected genes was
analyzed in three independent additional pairs of RNA from CAFs of BCC and
corresponding perifollicular fibroblasts. Bars indicate fold change of gene
expression in CAFs compared with their normal counterparts.
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Analysis of BCC-derived CAF gene set in other tumor types
To investigate if the set of novel CAF transcripts represented
genes commonly upregulated in CAFs of various tumor types,
or instead, were specifically regulated in BCC, the expression
of selected genes was additionally analyzed in CAFs from
human cutaneous squamous cell cancer (SCC), prostate, and
colon cancer.
Paired CAFs and corresponding normal dermal fibroblasts
were laser microdissected from tissue of four different SCC
patients. Amplification by qRT-PCR was successful for the
transcripts of SFRP2, MGP, ANGPTL2, and CTSK (Figure S1).
SFRP2 was upregulated in two of four preparations, and
ANGPTL2 was upregulated in one patient. While most of the
genes in the four SCC patients were not relevantly regulated,
in one patient all genes were clearly downregulated. The
expression of these genes was additionally analyzed in CAFs
from human prostate and colon cancer. Paired normal and
cancer fibroblasts were isolated by laser capture microdissec-
tion from five individuals of each of the two tumor types.
Owing to limited amounts of normal fibroblasts from colon
and prostate, the following analyses were performed on
pooled samples. Four pools of RNA were generated – from
normal fibroblasts of colon and prostate and the two
corresponding types of CAFs – and cDNA was prepared and
subjected to qRT-PCR (Figure S2). A moderate upregulation
of CTSK was seen in CAFs of colon cancer compared with
normal colon fibroblasts. MGP expression was significantly
increased in CAFs of prostate cancer. However, in general,
genes identified as being upregulated in CAFs of BCC did not
show consistent upregulation in the pools of CAFs derived
from these two tumor types. Although upregulation in
individual cases cannot be excluded, the analyses suggest
that the BCC genes are not consistently upregulated in CAFs
of prostate or colon cancer. In colon cancer, characterized by
its fast growth and metastasizing ability, most of the analyzed
genes were actually downregulated in CAFs (Figure S2).
These analyses thus revealed both similarities and
differences between the expression profiles of CAFs derived
from BCC and other tumor types.
DISCUSSION
In this study, we identified a novel set of genes, which were
consistently upregulated in CAFs of BCC. By comparing the
expression patterns of CAFs from BCC with other tumor types,
we conclude that CAFs in BCC display unique characteristics.
Finally, by combining laser capture microdissection with
microarray and qRT-PCR analyses, we present a robust
method for gene expression profiling of CAFs in situ, which is
less susceptible for confounding variables than traditional
detection methods and represents, in general, a powerful
approach for global analyses of tumor stroma.
Two general concerns relating to the combined amplifica-
tion and array approach that have been used in this study are
to what extent the array analyses reflect the original in situ
expression, and whether the findings are applicable outside
the tested individuals. In respect to the first of these concerns,
it should be noted that our fourteen qRT-PCR analyses,
including nine genes identified as differentially expressed,
provided strong evidence that the genes identified in the array
analyses are indeed differentially expressed in situ. In
general, the array experiments appeared to underestimate
the differential expression (Table 1), possibly due to a
reduced dynamic range as compared with qRT-PCR. Con-
cerning the issue of interindividual variation, it should be
noted firstly that the set of 13 genes encoding secreted
proteins were identified after analyses of three different
patients, and secondly that four of these genes –MGP, SFRP2,
ANGPL2, PDGFRL – were further analyzed by qRT-PCR in
three additional and independent cases. Independent support
for the validity of the approach is also provided by the fact
that our experiments also identified genes that were
previously known to be altered in the stroma of BCC
(Hunzelmann et al., 1995; Thewes et al., 1999).
BCC possesses unique growth characteristics including a
virtual inability to metastasize and an apparent dependence
on a specific loose connective tissue stroma. The crucial role
of the specific BCC stroma has been shown in auto-
transplantation experiments where human BCC devoid of
stroma failed to grow (Van Scott and Reinertson, 1961). The
close resemblance between developing hair follicles and
BCC with its cognate stroma has also been established in
several studies (Ponten et al., 1994). This study shows that
none of the analyzed BCC CAF genes display a consistent
upregulation in the other analyzed tumor types, including
SCC, and thus supports the general notion that the stroma of
BCC provides unique functions. The presented data set of
upregulated transcripts might contain genes and pathways
with key functions for stroma-dependent BCC growth. The
unraveling of such pathways might be one important step to
understand why BCC does not develop into a metastasizing
disease. Moreover, the obvious dependence of BCC on
specific factors derived from the stromal tissue makes CAFs
an interesting target in efforts to establish new treatment
strategies. From a more general perspective, it can also be
noted that the differences between CAFs and normal
fibroblasts in different tumor types might not only reflect
different dependencies of tumor support, but could also
reflect intrinsic differences in normal fibroblasts of different
organs, which might introduce tissue-specific needs for CAF
adaptation of tumor growth. Striking evidence for the tissue-
dependent differences in fibroblast expression profiles has
recently been presented (Chang et al., 2002; Rinn et al.,
2006).
In this study, we identified 13 genes, which encoded
secreted proteins. Six of these proteins were already
described in the context of fibroblast–epithelum interaction
in tumorigenesis of BCC or other cancer types. The protease
MMP11 (stromelysin-3) is frequently expressed in CAFs of
human BCC (Majmudar et al., 1994; Unden et al., 1996;
Thewes et al., 1999). Also the ‘‘matrikin’’ DCN was identified
as a fibroblast-derived proteoglycan in human BCC poten-
tially exhibiting tumor-promoting properties (Hunzelmann
et al., 1995; Tran et al., 2005). The glycoprotein SPARC
(osteonectin) is expressed in fibroblasts, smooth muscle, and
endothelial cells in the human dermis (Hunzelmann et al.,
1998). Very recently it was demonstrated that SPARC-null
www.jidonline.org 1519
P Micke et al.
Gene Expression in Fibroblasts of Basal Cell Carcinoma
mice were resistant to UV-induced SCC induction, suggesting
a tumor-promoting role of SPARC in skin (Aycock et al.,
2004). In addition, SPARC expression was associated with
melanoma progression in nude mice (Ledda et al., 1997), and
with poor clinical outcome in human small melanoma
lesions (Massi et al., 1999). In contrast, several studies
indicate a clearly opposite – tumor suppressive – effect of
SPARC in several cancer types (Koblinski et al., 2005; Said
and Motamed, 2005). In xenograft models SPARC inhibited
angiogenesis, resulting in reduced tumor growth, which was
accompanied by significant alterations in the ECM texture
(Chlenski et al., 2006). In accordance, authors demonstrated
significantly enhanced tumor growth in a syngenic mouse
model lacking endogenous SPARC (Brekken et al., 2003).
The seven novel genes identified as being upregulated in
CAFs of BCC were PDGFRL, SFRP2, ANGPTL2, CTSK, MGP,
CILP, and DPT.
PDGFRL and SFRP2 are secreted proteins, which have
been suggested to act as soluble scavenger receptors for
ligands binding to tyrosine kinase receptors and frizzled
receptors, respectively (Fujiwara et al., 1995; Lee et al.,
2004). ANGPTL2 shares structural similarities with the
angiopoietin family of proteins and has also been shown to
display angiogenic activity (Kim et al., 1999). CTSK, also
detected in osteoclasts and human breast carcinoma, is a
member of the cathepsin family of proteins, which recently
have attracted considerable interest based on association
with tissue invasion and metastases (Littlewood-Evans et al.,
1997; Joyce et al., 2004). MGP represents an osteogenic
protein involved in bone mineralization and also in vessel
calcification and fibrosis (Hauschka et al., 1989; Canfield
et al., 2002). Finally, CILP and DPT are both extracellular
matrix proteins with poorly characterized functions (Lorenzo
et al., 1998; Takeda et al., 2002). CILP is primarily expressed
in the human cartilage, but non-chondrogenic expression has
also been observed recently (Mori et al., 2006). DPT has been
implicated in connective tissue pathologies, including wound
healing, and has initially been identified as a molecule
associated with DCN (Forbes et al., 1994), which was also
recognized being upregulated in the stroma of our analyzed
BCC tissues. DPT is of significant importance for the elasticity
of the skin and has been suggested to enhance transforming
growth factor-b signaling in human skin fibroblasts by
modulation of its interaction with DCN (Kuroda et al.,
1999; Takeda et al., 2002).
Gene expression studies have also been performed
utilizing whole BCC tissue, that is, the mixture of cancer
cells, immune, and other stromal cells (Marionnet et al.,
2003; Howell et al., 2005). Some of the genes identified in
this study were also identified in these publications, such as
collagen type Va2, SPARC, and MMP11. However, the lack
of major overlap also emphasizes the need for separate
analyses of CAFs to unravel their characteristics as compared
with normal fibroblasts.
As an additional approach to compare the properties of
stromal fibroblasts, the results from this study were compared
with recent studies in other tumor types. Interestingly, an
overlap was observed between the present gene set and the
set of 45 secreted proteins and receptors that were shown to
be upregulated in CD10-positive non-epithelial cells of breast
cancer in situ (Allinen et al., 2004). Out of the 13 secreted
proteins and receptors of this data set, four proteins were
identified in both studies: CTSK, SFRP2, PDGFRL, and DCN.
In contrast, none of the annotated genes of this study
overlapped with the genes identified as being upregulated
in cultured CAFs derived from pancreatic cancer, liver
metastases of colon cancer, and mucinous cystic neoplasms
of the pancreas (Fukushima et al., 2004; Nakagawa et al.,
2004; Sato et al., 2004). However, it should be noted that two
of these latter studies analyzed cultured CAFs and, further-
more, none of the gene sets were derived by comparing CAFs
with the corresponding normal fibroblasts of the same
patient.
In summary, our study illustrates the potential of the
analysis of microdissected cells from its in situ environment
for tumor stroma characterization. Moreover, our results add
to recently accumulating data indicating consistent expres-
sion alterations in CAFs in various tumor types, as it provides
the first characterization of gene expression profiling of CAFs
in BCC compared with normal skin human fibroblasts. It is
likely that the continued characterization of this cross-talk
and the molecular identification of key mediators, will
provide insights into tumor biology as well as suggestions
for novel therapeutic opportunities.
MATERIALS AND METHODS
Human tissue samples
All tissue samples were collected and used in accordance with the
ethical rules of the Department of Pathology, Uppsala University
Hospital, Sweden and in agreement with the Swedish biobank
legislation and the Declaration of Helsinki Principles. Human tissue
samples were obtained from the Fresh Tissue Biobank, Department
of Pathology, Uppsala University Hospital, Sweden. In this project,
anonymized tumor and normal samples were collected from excess
tissue otherwise to be discarded after histopathological diagnosis, in
accordance with the Swedish biobank legislation and the Declara-
tion of Helsinki Principles. The fresh tissue were placed in
cryomolds, covered with cryogel (OCT, Histolab, Go¨teborg,
Sweden), frozen in isopentane/dry ice (1201C), and were finally
transferred to a low temperature freezer (801C). Patient character-
istics of BCC samples are illustrated in Table S2. Frozen tissue of
highly differentiated SCC of the skin was procured from four patients.
Human prostate cancer tissue was obtained after prostectomy from
five patients; human colon cancer tissue after colectomy from five
patients.
The specimens were cut into 10mm thick cryosections, mounted
on slides covered with a thin polyethylene membrane (P.A.L.M. AG,
Bernried, Germany), and were stored at 801C until final use.
Preparation of slides and laser capture microdissection
A detailed protocol has been previously published (Micke et al.,
2005). Immediately after removing the sections from the freezer,
50 ml hematoxylin mixed with 1ml RNAsin (5,000 U/l; Invitrogen,
Fredrick, MD) was applied onto the section for 2 minutes. The slides
were then washed in Zincfix buffer for 1 minute, followed by
consecutive dehydration for 30 seconds in 70, 95, and 100%
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ethanol. In order to improve morphology, if necessary, 50 ml of
PALM LiquidCoverglass (P.A.L.M. AG) diluted in isopropanol (1:3)
was applied directly on the tissue section (Micke et al., 2004). After
3 minutes of air drying, the sections were laser capture micro-
dissected following the manufacturers’ protocol for the PALM Laser-
MicroBeam System. A microfuge cap filled with 60 ml RNA
extraction reagent (Trizol, Invitrogen) was mounted upside down
just above the tissue section. To select and isolate areas of interest,
microdissection was performed by cutting with a focused laser beam
producing a gap of 1.0 mm around fibroblasts in vicinity of hair
follicles and fibroblasts in close neighborhood to BCC. The isolated
cells were separated and transferred to the upper cap with single
laser shots just below the focal plane of the tissue specimen. In each
session, approximately 300–1,000 cells were collected and imme-
diately frozen in Trizol at 801C.
RNA extraction and quantification
The volume of the Trizol solution was adjusted to 300, and 60 ml
chloroform–isoamylalcohol were added. After mixing, the phases
were separated by centrifugation (10,000 r.p.m., 10 minutes, at room
temperature). The aqueous phase was transferred to a new tube and
2ml co-precipitant (PelletPaint, Novagen, San Diego, CA) and 160 ml
isopropanol was added. After mixing and incubation for 5 minutes at
room temperature, RNA was precipitated by centrifugation
(13,000 r.p.m., 10 minutes at room temperature). The precipitate
was washed twice with 70% ethanol. After removal of the ethanol
and 15 minutes drying, the RNA was resolved in 20 ml RNAse free
water (Ambion, Austin, TX).
cDNA synthesis and qRT-PCR
To 10 ml RNA solution, 1ml oligo-dT primers (dT17) and 1ml 10 mM
dNTPmix (Clontech, Palo Alto, CA) were added. After heating for
10 minutes at 651C the samples were immediately chilled on ice.
Reverse transcription was performed at 421C for 1 hour after adding
4ml first strand buffer, 2ml dithiothreitol, 1ml RNAsin (Promega,
Mannheim, Germany), and 1ml Superscript II reverse-transcriptase
(Invitrogen). The reaction was inactivated at 651C for 20 minutes
and RNA was digested with 1ml RNAse H (Clontech) for 30
minutes at 371C. Two microliters (10 %) was then used for a
50-cycle Sybrgreen PCR assay using the Sybrgreen Universal
PCR Master Mix (Applied Biosystems, Foster City, CA). Primer
sequences were given in the supplements of the on-line version
(Table S3). The reaction was performed with the ABI PRISM 7000HT
real-time PCR cycler (Applied Biosystems) under conditions recom-
mended by the manufacturer. Expression levels were normalized to
the house-keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
RNA amplification
The RNA amplification was performed according to the linear T7-
based amplification protocol of Scheidl et al. (2002) as described. In
general, 2–4 rounds of amplification were performed until at least
2mg of double stranded DNA were available. The last in vitro
transcription reaction included an incorporation of dye-labeled
nucleotides (Cy3 or Cy5). To 2 mg of double stranded DNA (adjusted
to 9ml), 2.5 ml transcription reaction buffer (T7 Megascript kit,
Ambion), 2 ml ATP, 2ml CTP, 2 ml GTP, 1.5 ml UTP (T7 Megascript kit,
Ambion), 2 ml enzyme mix (T7 Megascript kit, Ambion), 1ml RNAsin
(Promega), and 3 ml Cy5/Cy3-UTP (Amersham Bioscience, Uppsala,
Sweden) were added. The sample was incubated overnight at 371C.
The template DNA was removed by addition of 0.5 ml DNAse
treatment (T7 Megascript kit, Ambion). The RNA was purified with
AutoSec G column (Amersham Bioscience) according to the
manufacturer’s protocol.
Microarray hybridization
Gene expression analyses were performed using microarray chips
from the Welcome Trust Sanger Institute (human version 1.2.1),
containing roughly 10,000 elements, corresponding to about 6,000
individual genes. RNA from each sample was hybridized, together
with the reference sample, in quadruplicate as duplicate dye-swaps.
For detailed description of arrays and protocols see http://www.san-
ger.ac.uk/Projects/Microarrays/. After hybridization, chips were
scanned with a ScanArray 5000 (GSI Lumonics, Warwickshire,
UK) using the ScannArray software version 3.1 (Packard BioChip
Technologies, Billerica, MA). Expression intensity values were
quantified by using the QuantArray software version 3.0.0.0
(Packard BioChip Technologies). Unreliable spots were flagged
manually and signals were quantified by the histogram method.
Statistics
Data from microarray analyses were loaded into GeneSpring,
normalized by the LOWESS method, and evaluation was performed
according to a standardized algorithm. cDNA elements were defined
as upregulated, if the average of the four replicates show at least 1.7-
fold upregulation and thus significantly differ from 1 (t-test, Po0.05).
In correspondence, cDNA spots with mean expression o0.57 and
significant differences from 1 (t-test, Po0.05) were defined as being
downregulated.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
The study was supported by a grant to PM from the Dr Mildred Scheel
Cancer Foundation (Germany) and by grants from the Swedish Cancer
Foundation (AO¨ and FP), the Karolinska Institute (AO¨), the Deutsche
Forschungsgemeinschaft (KA 1820/1-1 to KK), and a grant-in-aid for
scientific research from the Japan Society for the Promotion of Science (no.
16209063 to MO). Aris Moustakas, Daniel Ha¨gerstrand, and Marcin
Kowanetz are acknowledged for their assistance with gene array analysis.
The microarray consortium is funded by the Wellcome Trust, Cancer
Research UK and the Ludwig Institute for Cancer Research. We wish to
thank the staff of the Sanger Institute Microarray Facility http://www.sanger.
ac.uk/Projects/Microarrays/ for supplying arrays, lab protocols, technical
advice (David Vetrie, Cordelia Langford, Adam Whittaker, and Neil Sutton),
and Quantarray/GeneSpring datafiles and databases relating to array elements
(Kate Rice, Rob Andrews, Adam Butler, and Harish Chudasama). The human
IMAGE cDNA clone collection was from the MRC HGMP Resource
Centre (Hinxton, UK). cDNA clone resequencing was performed by Team
56 at the Sanger Institute.
SUPPLEMENTARY MATERIAL
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